MFN Pricing Deals as Tariff Insurance: How Pharma Companies Are Buying Their Way Out of 100% Tariffs

Pharmaceutical companies now face an unusual trade-off: accept lower US drug prices in exchange for protection from the harshest import tariffs. Under the April 2026 Section 232 framework, companies that enter qualifying Most Favored Nation pricing and onshoring agreements can receive a zero tariff rate on covered patented pharmaceuticals and associated APIs through January 20, 2029.

That makes MFN negotiations more than a drug-pricing exercise. For manufacturers with substantial overseas production, the agreements can function as a form of tariff insurance, exchanging part of the US pricing opportunity for greater certainty over import costs.

For procurement teams, API suppliers and pharmaceutical manufacturers, the critical question is whether the savings from tariff avoidance outweigh the revenue surrendered through lower US prices.

How MFN Pricing Became Linked to Pharmaceutical Tariff Relief

The US MFN initiative began as a mechanism to bring American drug prices closer to the lowest prices paid in other developed countries.

By February 2026, the administration had launched TrumpRx.gov, featuring medicines from manufacturers that had reached MFN agreements. The initial group included AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer.

The April Section 232 proclamation connected that pricing framework directly with trade policy.

The proclamation established a 100% tariff on covered patented pharmaceuticals and associated pharmaceutical ingredients while providing a zero-tariff pathway for companies that enter qualifying MFN and onshoring agreements.

This creates a powerful negotiating mechanism.

A manufacturer can potentially reduce its US pricing while eliminating an import cost that could otherwise equal the value of the imported product itself.

The 100% Tariff Makes the Calculation Material

A 100% ad valorem tariff changes the economics of imported pharmaceuticals dramatically.

Consider a simplified shipment with a customs value of $10 million. A 100% tariff would create $10 million in tariff liability before other applicable costs.

That makes the tariff more than a marginal supply-chain expense. It can fundamentally change the profitability of an imported product.

The April proclamation establishes the 100% rate for covered patented pharmaceuticals and associated ingredients, while setting a 20% rate for companies with approved onshoring plans. The 20% rate is scheduled to rise to 100% on April 2, 2030.

For companies with large US sales and significant foreign manufacturing exposure, negotiating an MFN agreement can therefore become economically attractive even when the pricing concession is substantial.

Zero Tariff Is the Strongest MFN Incentive

The most important feature for manufacturers is not simply the MFN price.

It is the combination of price concessions and tariff treatment.

Under the April proclamation, companies eligible for the 20% onshoring pathway that also enter MFN pharmaceutical pricing agreements can receive a zero tariff rate until January 20, 2029. The government can also apply the zero rate to companies considered likely to become eligible, including those with agreements in principle.

That creates a direct commercial equation:

Lower US drug prices + onshoring commitments = potential tariff savings and greater import certainty.

For some manufacturers, the tariff savings may outweigh the reduction in US pricing.

For others, particularly companies with relatively low import exposure or highly profitable US products, the pricing concession may be harder to justify.

The MFN Trade-Off Is Bigger Than a Simple Discount

MFN pricing affects more than one sales channel.

The administration's framework requires manufacturers to offer existing covered drugs to state Medicaid programs at MFN prices. For future launches, the framework extends MFN principles across US markets, including private insurance, according to a May 2026 White House report.

The direct-to-consumer channel adds another dimension.

TrumpRx.gov provides discounted cash prices for participating medicines, allowing patients without traditional insurance coverage to access lower prices. The administration has positioned this channel as part of the broader MFN framework.

This means manufacturers need to model the impact across multiple revenue channels rather than simply comparing an MFN price with the current list price.

Medicaid Becomes a Major Part of the Bargain

State Medicaid programs sit at the center of the MFN structure for existing medicines.

The White House estimated that MFN pricing for existing drugs in Medicaid could generate $64.3 billion in federal and state savings over 10 years. It also projected substantial savings from prospective MFN pricing for future launches.

For pharmaceutical manufacturers, this creates a significant revenue consideration.

A company agreeing to MFN pricing may give up pricing power in one of the largest regulated purchasing channels in exchange for broader policy benefits, including tariff treatment and a more predictable trade environment.

That is why finance, government affairs, manufacturing and procurement teams increasingly need to evaluate the agreements together.